Opendata, web and dolomites

BERMES SIGNED

A Novel BERberine derivative for Malignant MESothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BERMES project word cloud

Explore the words cloud of the BERMES project. It provides you a very rough idea of what is the project "BERMES" about.

despite    arising    data    berberine    treatment    pulling    cavity    therapy    antitumour    preliminary    close    nax035    obtaining    union    derivative    heart    solved    incidences    last    2020    resistant    aggressive    translational    valley    regulatory    right    malignant    survival    mesothelioma    thin    banned    mm    world    efficacy    agency    undertaken    2005    toxicity    line    oral    trials    asbestos    latency    emergence    drug    combination    improvement    tissue    peak    forms    completion    44    diagnosis    pharmacokinetic    standard    drugs    definitely    pemetrexed    organs    cisplatin    administered    innovative    authorization    manufacture    layer    period    first    covers    january    lungs    malignancy    clinical    testis    trial    exhibited    orphan    burden    health    mesothelium    exposure    chemoresistance    rare    none    death    bermes    agent    medicine    shown    internal    worldwide    disease    designation    good    deal    safety    peritoneal    organization    gap    limited   

Project "BERMES" data sheet

The following table provides information about the project.

Coordinator
APPLIED RESEARCH USING OMIC SCIENCES SL 

Organization address
address: CALLE VICTOR PRADERA 45
city: CORNELLA
postcode: 8940
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙550˙942 €
 EC max contribution 1˙085˙659 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    APPLIED RESEARCH USING OMIC SCIENCES SL ES (CORNELLA) coordinator 1˙085˙659.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis. The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020. The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance. NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BERMES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BERMES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More